Abstract PS1-12-29: Real-world outcomes of second-line therapies in HR+/HER2- metastatic breast cancer after progression on CDK4/6 inhibitor
View Full Paper
Ask AI
Bookmark
Share
Key Points
This research aims to evaluate the efficacy of second-line therapies in HR+/HER2- metastatic breast cancer after progression on CDK4/6 inhibitors.
Conducted a single center cohort study on patients initiating second-line therapy after first-line treatment with CDK4/6 inhibitors.
Assessed progression-free survival (PFS) and overall survival (OS) based on treatment types.
Utilized Kaplan-Meier method and multivariable Cox regression models for outcome analysis.
Included 281 women with median age 67 years; majority postmenopausal with varied metastatic sites.
Patients treated with everolimus had a median PFS of 4.9 months and OS of 23.4 months; chemotherapy showed a median PFS of 4.4 months and OS of 14.9 months.
Higher risk of death observed for chemotherapy versus everolimus treatment with HR = 1.80, indicating significant treatment differences.